Merit Medical (MMSI) Systems announced enrollment of the first patient in its multicenter, prospective study of the Bloom Micro Occluder System for the treatment of patent ductus arteriosus in premature infants.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MMSI:
- Tariff delay positive for Mexico-exposed medtech companies, says BofA
- Merit Medical’s Earnings Call Highlights Growth and Challenges
- Merit Medical price target lowered to $111 from $115 at Barrington
- Merit Medical price target lowered to $116 from $122 at Needham
- Merit Medical price target lowered to $127 from $128 at Canaccord